L-Citrulline

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: muscle energy heart

Research Overview

Across the cited literature, L-citrulline research is most concentrated in cardiometabolic physiology, particularly its role in nitric oxide (NO) biology via the L-citrulline–L-arginine recycling pathway and downstream vascular effects. Compared with oral L-arginine, L-citrulline is emphasized as a more effective strategy to raise systemic L-arginine availability because it is less extensively extracted by the gut and liver, thereby potentially supporting endothelial NO production. Consistent with this mechanistic focus, evidence syntheses of randomized trials place L-citrulline among micronutrient supplements with moderate- to high-quality evidence for improving cardiovascular risk factors (e.g., blood pressure and related hemodynamic measures), although the strongest clinical-event evidence in the meta-analytic map is for other nutrients (e.g., n-3 fatty acids for CVD events; folic acid for stroke). Mechanistic vascular reviews further contextualize why NO bioavailability can remain impaired in cardiometabolic disease (e.g., oxidative stress, eNOS uncoupling), suggesting that L-citrulline’s benefits may depend on broader redox/endothelial conditions.

The strongest support from these abstracts is therefore for L-citrulline as a plausible, mechanistically grounded intervention to improve NO-related vascular function and to lower blood pressure in adults with prehypertension/hypertension, with additional preliminary signals for benefits to muscle and metabolic health in older or susceptible populations. Beyond cardiometabolic outcomes, emerging preclinical work identifies a microbiota–metabolite axis in which microbial production of L-citrulline (and conversion to L-arginine) enhances bone mechanoadaptation in mice, including aged and ovariectomized models, via an NO–calcium feedback mechanism in osteocytes—positioning L-citrulline as a candidate adjunct to mechanical loading for osteoporosis prevention. Separate animal-nutrition literature also discusses L-citrulline as a functional additive under heat stress in poultry, but this area is comparatively less developed and not directly translatable to human clinical practice without further evidence.

Key gaps include the need for larger, well-controlled human trials that move beyond intermediate risk factors to evaluate hard clinical endpoints (e.g., myocardial infarction, stroke), and to define optimal dosing, duration, and target populations (including those with endothelial dysfunction, older adults, and individuals with metabolic disease). Additional research is needed to clarify effect modifiers such as baseline NO/oxidative stress status, interactions with therapies that influence endothelial redox biology (e.g., statins or renin–angiotensin system inhibitors), and whether combined strategies (e.g., L-citrulline plus interventions that reduce oxidative stress/eNOS uncoupling) yield greater benefit. Finally, the microbiome–bone findings warrant translational studies to determine whether similar metabolite-mediated enhancements of skeletal mechanosensitivity occur in humans, and poultry heat-stress applications require more standardized, mechanistic, and outcome-focused studies to establish consistency and practical relevance.

1. What conditions has L-Citrulline been studied for?

  • Cardiovascular risk factors and cardiometabolic health: Included among micronutrients with moderate- to high-quality evidence for reducing CVD risk factors in a large systematic review/meta-analysis of randomized trials (the abstract lists L-citrulline among effective supplements for CVD risk factors, though it does not provide L-citrulline-specific effect sizes).

  • Elevated blood pressure (pre-hypertension/hypertension): A review describes L-citrulline as promising for lowering resting and stress-induced blood pressure in adults with pre-/hypertension; another review specifically evaluates oral L-arginine and L-citrulline for BP reduction and provides estimated BP-lowering ranges for L-citrulline.

  • Endothelial dysfunction / nitric oxide (NO) bioavailability impairment: Multiple abstracts focus on NO biology and the L-arginine–L-citrulline cycle, positioning L-citrulline as a strategy to raise L-arginine and support NO synthesis when NO bioavailability is diminished (e.g., in diabetes, hypertension, hypercholesterolaemia, smoking—though these are discussed as risk-factor contexts rather than direct L-citrulline trials in the provided text).

  • Muscle and metabolic health in older/susceptible populations: One review notes “preliminary evidence” for benefits to muscle and metabolic health via vascular and non-vascular pathways.

  • Exercise performance/tolerance (via NO-donor concept): A review of NO donors (including L-citrulline as an indirect NO donor via conversion to L-arginine) discusses mixed performance findings and suggests effects may depend on training status.

  • Bone health/osteoporosis-related outcomes (preclinical): In mice, microbial production of L-citrulline and conversion to L-arginine were identified as regulators of bone mechanoadaptation; administration of these metabolites enhanced bone responsiveness to mechanical loading in normal, aged, and ovariectomized mice.

  • Critical illness, catabolic states, low protein intake (as an “anabolic pharmaconutrient”): A review suggests L-citrulline may be a safer way to deliver arginine to endothelial/immune cells and may support protein synthesis (mechanistically linked to mTOR), including potential use in critically ill patients.

  • Urea cycle disorders (clinical use): The abstract states L-citrulline is “safely used from the neonatal period onwards” in certain urea cycle defects (carbamyl phosphate synthetase or ornithine transcarbamylase deficiencies).

  • Heat stress in poultry (animal nutrition): A poultry-focused review discusses L-citrulline as a functional additive during heat stress, with limited poultry-specific evidence noted.

2. Does it work in treating those conditions? Summarize the evidence.

  • Blood pressure: Evidence is suggestive but not uniformly definitive across reviews.

    • One review reports L-citrulline supplementation has “shown promise” for lowering resting and stress-induced BP in adults with pre-/hypertension.

    • Another review concludes L-citrulline’s antihypertensive properties are “more questionable,” but likely within an estimated range of about 4.1/2.08 to 7.54/3.77 mmHg (systolic/diastolic) reduction. (The abstract provides ranges rather than a single pooled estimate.)

    • Mechanistic plausibility is emphasized: L-citrulline is described as more effective than oral L-arginine at raising L-arginine and NO synthesis because it bypasses substantial gut/liver first-pass extraction.

  • CVD risk factors (broad): A large systematic review/meta-analysis of randomized trials lists L-citrulline among supplements with moderate- to high-quality evidence for reducing CVD risk factors, but the abstract does not provide L-citrulline-specific outcomes or effect sizes, limiting condition-specific conclusions from that source alone.

  • Exercise performance: Evidence is mixed for NO-donor supplementation overall.

    • The exercise-focused review notes discrepancies: some studies show improved tolerance to aerobic/anaerobic exercise, others show no benefit.

    • Training status appears important: benefits are more often reported in untrained/moderately trained individuals, while highly trained subjects often show no performance improvement.

    • The abstract discusses NO donors broadly (including L-citrulline as an indirect donor), so it does not establish a consistent, L-citrulline-specific ergogenic effect.

  • Bone mechanoadaptation/osteoporosis (preclinical): In mice, administration of L-citrulline and/or L-arginine enhanced skeletal adaptation to mechanical loading in normal, aged, and ovariectomized models, with a proposed osteocyte nitric-oxide–calcium feedback mechanism. This is promising but animal evidence, not proof of efficacy in humans.

  • Critical illness/catabolic states: The abstract characterizes evidence as “animal studies and early human data” indicating positive effects on protein synthesis (linked to mTOR) and suggests L-citrulline can be safely administered even in critically ill patients. However, the abstract does not provide clinical endpoints or trial results sufficient to confirm treatment efficacy.

  • Urea cycle disorders: The abstract states L-citrulline is safely used from the neonatal period in specific urea cycle defects, implying established clinical utility in that context (as part of metabolic management), though no efficacy metrics are provided in the abstract.

  • Heat stress in poultry: The poultry review notes variable findings for amino acid strategies overall and explicitly states there is limited information on use during heat stress in poultry nutrition, so efficacy is not established.

3. What health benefits does it have?

  • Supports nitric oxide biology and endothelial function (mechanistic benefit):

    • L-citrulline is described as more effective than oral L-arginine at increasing L-arginine levels because it is not “quantitatively extracted” by enterocytes/liver, improving substrate availability for eNOS and NO synthesis.

    • This is relevant because diminished NO bioavailability is linked (in the abstracts) to age- and lifestyle-related diseases and cardiovascular risk-factor states.

  • Blood pressure lowering:

    • Reviews describe BP-lowering promise in pre-/hypertension (including stress-induced BP), with estimated reductions in the range of several mmHg in the BP-focused review.

  • Potential cardiometabolic risk-factor improvement:

    • The large systematic review/meta-analysis lists L-citrulline among micronutrients with moderate- to high-quality evidence for reducing CVD risk factors (without specifying which risk factors in the abstract).

  • Potential muscle/metabolic benefits in older or susceptible groups:

    • A review notes preliminary evidence for benefits to muscle and metabolic health via vascular and non-vascular pathways.

  • Potential anabolic/protein synthesis support:

    • A review suggests L-citrulline may support protein synthesis (proposed mTOR involvement) and may be useful when endogenous arginine synthesis is insufficient (e.g., low protein intake, catabolic states).

  • Bone health (preclinical):

    • In mice, L-citrulline/L-arginine administration enhanced bone responsiveness to mechanical loading, including in aged and ovariectomized models, suggesting a potential anti-osteoporotic strategy (not yet confirmed in humans).

4. Does it have any downsides or side effects?

  • Safety/tolerability (as described in the abstracts):

    • One abstract states L-citrulline is “safely used from the neonatal period onwards” in certain urea cycle defects and can be “safely administered even in critically ill patients,” supporting a generally favorable safety profile in clinical contexts mentioned.

  • Limitations/uncertainties rather than clear harms:

    • The BP review notes L-citrulline’s antihypertensive effects are “more questionable” than L-arginine’s in the available data, implying variability across studies and uncertainty about magnitude/consistency.

    • The exercise review highlights inconsistent performance outcomes for NO-donor supplementation and suggests effects depend on training status; this is a “downside” in terms of predictability rather than safety.

  • Side effects not detailed in provided abstracts:

    • The supplied abstracts do not enumerate common adverse effects (e.g., gastrointestinal symptoms) or specific contraindications/drug interactions for L-citrulline, so no evidence-based side-effect frequency can be concluded from this set alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • No direct pharmacogenomic evidence in the provided abstracts: None of the abstracts report outcomes stratified by genotype or specific genetic variants affecting L-citrulline response (e.g., NOS3/eNOS polymorphisms, argininosuccinate synthase/lyase variants outside of urea cycle disorders, or transport/metabolism genes).

  • Genetic disease context (not pharmacogenomics of response, but relevant):

    • L-citrulline is described as safely used in specific urea cycle defects (carbamyl phosphate synthetase or ornithine transcarbamylase deficiencies). This indicates clinical relevance in inherited metabolic disorders, but the abstract does not provide genotype-specific dosing/response or comparative outcomes.

  • Mechanistic plausibility without genetic confirmation: Because the abstracts emphasize NO biology and L-citrulline-to-L-arginine recycling, it is plausible that variants affecting NO synthesis/oxidative stress pathways could influence response, but this is not tested or established in the provided evidence.

References

  1. Micronutrient Supplementation to Reduce Cardiovascular Risk.
    Peng An, Sitong Wan, Yongting Luo, Junjie Luo, Xu Zhang, Shuaishuai Zhou, Teng Xu, Jingjing He, Jeffrey I Mechanick, Wen-Chih Wu, Fazheng Ren, Simin Liu (2022) - Journal of the American College of Cardiology
  2. l-Citrulline Supplementation: Impact on Cardiometabolic Health.
    Timothy D Allerton, David N Proctor, Jacqueline M Stephens, Tammy R Dugas, Guillaume Spielmann, Brian A Irving (2018) - Nutrients
  3. Functional roles of taurine, L-theanine, L-citrulline, and betaine during heat stress in poultry.
    Victoria Anthony Uyanga, Emmanuel O Oke, Felix Kwame Amevor, Jingpeng Zhao, Xiaojuan Wang, Hongchao Jiao, Okanlawon M Onagbesan, Hai Lin (2022) - Journal of animal science and biotechnology
  4. Gut microbial alterations in arginine metabolism determine bone mechanical adaptation.
    Dan Wang, Jing Cai, Qilin Pei, Zedong Yan, Feng Zhu, Zhe Zhao, Ruobing Liu, Xiangyang Guo, Tao Sun, Juan Liu, Yulan Tian, Hongbo Liu, Xi Shao, Jinghui Huang, Xiaoxia Hao, Qi Chang, Zhuojing Luo, Da Jing (2024) - Cell metabolism
  5. Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling.
    Ulrich Förstermann, Huige Li (2011) - British journal of pharmacology
  6. Mitochondrial Fission as a Therapeutic Target for Metabolic Diseases: Insights into Antioxidant Strategies.
    Tianzheng Yu, Li Wang, Lei Zhang, Patricia A Deuster (2023) - Antioxidants (Basel, Switzerland)
  7. The effect of nitric-oxide-related supplements on human performance.
    Raúl Bescós, Antoni Sureda, Josep A Tur, Antoni Pons (2012) - Sports medicine (Auckland, N.Z.)
  8. The Effects of Oral l-Arginine and l-Citrulline Supplementation on Blood Pressure.
    David Khalaf, Marcus Krüger, Markus Wehland, Manfred Infanger, Daniela Grimm (2019) - Nutrients
  9. Citrulline in health and disease. Review on human studies.
    Cinzia Papadia, Sylwia Osowska, Luc Cynober, Alastair Forbes (2018) - Clinical nutrition (Edinburgh, Scotland)
  10. Dietary Arginine and Citrulline Supplements for Cardiovascular Health and Athletic Performance: A Narrative Review.
    Hun-Young Park, Sung-Woo Kim, Jisoo Seo, Yanghoon P Jung, Hyunji Kim, Ah-Jin Kim, Sonwoo Kim, Kiwon Lim (2023) - Nutrients
  11. L-Arginine Nutrition and Metabolism in Ruminants.
    Guoyao Wu, Fuller W Bazer, M Carey Satterfield, Kyler R Gilbreath, Erin A Posey, Yuxiang Sun (2022) - Advances in experimental medicine and biology
  12. Influence of L-citrulline and watermelon supplementation on vascular function and exercise performance.
    Arturo Figueroa, Alexei Wong, Salvador J Jaime, Joaquin U Gonzales (2017) - Current opinion in clinical nutrition and metabolic care
  13. Therapeutic Potential of Citrulline as an Arginine Supplement: A Clinical Pharmacology Review.
    Jahidur Rashid, Shaun S Kumar, Kathleen M Job, Xiaoxi Liu, Candice D Fike, Catherine M T Sherwin (2020) - Paediatric drugs
  14. Effect of food sources of nitrate, polyphenols, L-arginine and L-citrulline on endurance exercise performance: a systematic review and meta-analysis of randomised controlled trials.
    Noah M A d'Unienville, Henry T Blake, Alison M Coates, Alison M Hill, Maximillian J Nelson, Jonathan D Buckley (2021) - Journal of the International Society of Sports Nutrition
  15. L-Citrulline Ameliorates Iron Metabolism and Mitochondrial Quality Control via Activating AMPK Pathway in Intestine and Improves Microbiota in Mice with Iron Overload.
    Dai Zhao, Yuan Gao, Yiqin Chen, Yingsi Zhang, Yian Deng, Sai Niu, Hanchuan Dai (2024) - Molecular nutrition & food research
  16. Arginine Therapy for Lung Diseases.
    Jeremy A Scott, Harm Maarsingh, Fernando Holguin, Hartmut Grasemann (2021) - Frontiers in pharmacology
  17. Citrulline, Biomarker of Enterocyte Functional Mass and Dietary Supplement. Metabolism, Transport, and Current Evidence for Clinical Use.
    Stefano Maric, Tanja Restin, Julian Louis Muff, Simone Mafalda Camargo, Laura Chiara Guglielmetti, Stefan Gerhard Holland-Cunz, Pascal Crenn, Raphael Nicolas Vuille-Dit-Bille (2021) - Nutrients
  18. Dietary supplements for improving nitric-oxide synthesis.
    Aysha Karim Kiani, Gabriele Bonetti, Maria Chiara Medori, Paola Caruso, Paolo Manganotti, Francesco Fioretti, Savina Nodari, Stephen Thaddeus Connelly, Matteo Bertelli (2022) - Journal of preventive medicine and hygiene
  19. Homoarginine in health and disease.
    Dimitrios Tsikas (2023) - Current opinion in clinical nutrition and metabolic care
  20. Effects of Combined Versus Single Supplementation of Creatine, Beta-Alanine, and L-Citrulline During Short Sprint Interval Training on Basketball Players' Performance: A Double-Blind Randomized Placebo-Controlled Trial.
    Menghao Li, Mohsen Sheykhlouvand (2025) - International journal of sports physiology and performance


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!